留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

细胞游离DNA在器官移植中的应用

郎吉萍 苗芸

郎吉萍, 苗芸. 细胞游离DNA在器官移植中的应用[J]. 器官移植, 2018, 9(6): 460-462. doi: 10.3969/j.issn.1674-7445.2018.06.012
引用本文: 郎吉萍, 苗芸. 细胞游离DNA在器官移植中的应用[J]. 器官移植, 2018, 9(6): 460-462. doi: 10.3969/j.issn.1674-7445.2018.06.012

细胞游离DNA在器官移植中的应用

doi: 10.3969/j.issn.1674-7445.2018.06.012
基金项目: 

国家自然科学基金 81500573

广东省高等教育学会高等教育科学研究“十三五”规划重点调研课题 16GZD009

广州市科技计划项目 201803010109

南方医科大学大学生创新创业训练项目基金 201712121307

南方医科大学大学生创新创业训练项目基金 201812121251

详细信息
    作者简介:

    郎吉萍,女,1995年生,南方医科大学临床医学八年制,研究方向为细胞游离DNA的应用,Email:893273759@qq.com

    通讯作者:

    苗芸,女,1978年生,博士后,副主任医师,研究方向为器官移植的供体保存,Email:miaoyunecho@126.com

  • 中图分类号: R617

  • 摘要: 细胞游离DNA(cfDNA)是存在于体液中、游离于细胞外的DNA片段,其主要来源于血细胞、组织细胞、脂肪细胞等,在特定条件下还可能来源于肿瘤、移植物或胎儿等。随着精准医疗时代的到来,基于cfDNA检测的液体活组织检查技术在产前诊断、恶性肿瘤以及器官移植等领域中具有明显优势,其无创诊断、治疗监测以及预后评估等方面受到广泛关注。本文就cfDNA的生物学基础、cfDNA在器官移植中的应用做一综述。

     

  • [1] SNYDER MW, KIRCHER M, HILL AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin[J]. Cell, 2016, 164(1/2): 57-68. DOI: 10.1016/j.cell.2015.11.050.
    [2] CELEC P, VLKOVÁ B, LAUKOVÁ L, et al. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases[J]. Expert Rev Mol Med, 2018, 20: e1. DOI: 10.1017/erm.2017.12.
    [3] ALLAM R, KUMAR SV, DARISIPUDI MN, et al. Extracellular histones in tissue injury and inflammation[J]. J Mol Med (Berl), 2014, 92(5): 465-472. DOI: 10.1007/s00109-014-1148-z.
    [4] ULZ P, HEITZER E, GEIGL JB, et al. Patient monitoring through liquid biopsies using circulating tumor DNA[J]. Int J Cancer, 2017, 141(5): 887-896. DOI: 10.1002/ijc.30759.
    [5] YU SC, LEE SW, JIANG P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J]. Clin Chem, 2013, 59(8): 1228-1237. DOI: 10.1373/clinchem.2013.203679.
    [6] KHIER S, LOHAN L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature[J]. Future Sci OA, 2018, 4(4): FSO295. DOI: 10.4155/fsoa-2017-0140.
    [7] TOSEVSKA A, FRANZKE B, HOFMANN M, et al. Circulating cell-free DNA, telomere length and bilirubin in the vienna active ageing study: exploratory analysis of a randomized, controlled trial[J]. Sci Rep, 2016, 6: 38084. DOI: 10.1038/srep38084.
    [8] LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26. DOI: 10.1002/lt.23566.
    [9] MEEUSEN JW, LIESKE JC. Looking for a better creatinine[J]. Clin Chem, 2014, 60(8):1036-1039. DOI: 10.1373/clinchem.2013.220764.
    [10] LO YM, TEIN MS, PANG CC, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients[J]. Lancet, 1998, 351(9112): 1329-1330. doi: 10.1016/S0140-6736(05)79055-3
    [11] BECK J, OELLERICH M, SCHULZ U, et al. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation[J]. Transplant Proc, 2015, 47(8): 2400-2403. DOI: 10.1016/j.transproceed.2015.08.035.
    [12] GIELIS EM, LEDEGANCK KJ, DE WINTER BY, et al. Cell-free DNA: an upcoming biomarker in transplantation[J]. Am J Transplant, 2015, 15(10): 2541-2551. DOI: 10.1111/ajt.13387.
    [13] DE VLAMINCK I, MARTIN L, KERTESZ M, et al. Noninvasive monitoring of infection and rejection after lung transplantation[J]. Proc Natl Acad Sci U S A, 2015, 112(43): 13336-13341. DOI: 10.1073/pnas.1517494112.
    [14] DE VLAMINCK I, VALANTINE HA, SNYDER TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection[J]. Sci Transl Med, 2014, 6(241): 241ra77. DOI: 10.1126/scitranslmed.3007803.
    [15] BECK J, BIERAU S, BALZER S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury[J]. Clin Chem, 2013, 59(12): 1732-1741. DOI: 10.1373/clinchem.2013.210328.
    [16] SCHÜTZ E, FISCHER A, BECK J, et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study[J]. PLoS Med, 2017, 14(4): e1002286. DOI: 10.1371/journal.pmed.1002286.
    [17] SUN K, JIANG P, CHAN KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments[J]. Proc Natl Acad Sci U S A, 2015, 112(40): E5503-E5512. DOI: 10.1073/pnas.1508736112.
    [18] BLOOM RD, BROMBERG JS, POGGIO ED, et al. Cell-free DNA and active rejection in kidney allografts[J]. J Am Soc Nephrol, 2017, 28(7): 2221-2232. DOI: 10.1681/ASN.2016091034.
    [19] BROMBERG JS, BRENNAN DC, POGGIO E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications[J]. J Appl Lab Med, 2017, 2(3): 309-321. DOI: 10.1373/jalm.2016.022731.
    [20] OELLERICH M, SCHÜTZ E, KANZOW P, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation[J]. Ther Drug Monit, 2014, 36(2): 136-140. DOI: 10.1097/FTD.0000000000000044.
    [21] OELLERICH M, WALSON PD, BECK J, et al. Graft-derived cell-free DNA as a marker of transplant graft injury[J]. Ther Drug Monit, 2016, 38(Suppl 1): S75-S79. DOI: 10.1097/FTD.0000000000000239.
  • 加载中
计量
  • 文章访问数:  240
  • HTML全文浏览量:  215
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-08-16
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2018-11-15

目录

    /

    返回文章
    返回